Managers / Q2 2024
HoyleCohen, LLC
CIK 0001559077 · 350 CAMINO DE LA REINA, SUITE 500, SAN DIEGO, CA, 92108 · 858-576-7300
Summary
Hoylecohen, LLC reported $1.3B in U.S.-listed holdings across 275 positions for Q2 2024.
Its largest position, AAPL, represents 9.5% of the portfolio.
Compared with Q1 2024, the fund opened 21 new positions and exited 28.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 70.2% · $928M
- ETP · 25.1% · $332M
- Other · 1.9% · $25M
- REIT · 1.5% · $20M
- MLP · 0.8% · $11M
- Other · 0.5% · $7M
Quarter-over-Quarter Changes full breakdown →
vs Q1 2024 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| VANGUARD SCOTTSDALE FDS | NEW | +57.7K | 57.7K | +$5M | $5M |
| VANGUARD SCOTTSDALE FDS | NEW | +31.8K | 31.8K | +$2M | $2M |
| CPCANADIAN PACIFIC KANSAS CITY | NEW | +27.1K | 27.1K | +$2M | $2M |
| VANGUARD SCOTTSDALE FDS | NEW | +17.0K | 17.0K | +$1M | $1M |
| MPCMARATHON PETE CORP | NEW | +2.3K | 2.3K | +$400,045 | $400,045 |
| ISHARES TR | NEW | +2.7K | 2.7K | +$367,583 | $367,583 |
| RXRXRECURSION PHARMACEUTICALS IN | NEW | +45.5K | 45.5K | +$341,415 | $341,415 |
| VRTXVERTEX PHARMACEUTICALS INC | NEW | +722 | 722 | +$338,416 | $338,416 |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q2 2024
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q2 2024 | $1.3B | 275 | Jul 19, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $1.3B | 282 | May 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $1.2B | 271 | Feb 9, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $1.1B | 260 | Nov 2, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $1.1B | 261 | Aug 7, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $1.1B | 258 | May 5, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $1.0B | 264 | Feb 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $913M | 258 | Nov 2, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $960M | 260 | Jul 27, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $1.2B | 274 | May 3, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $1.2B | 277 | Feb 11, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $1.1B | 267 | Nov 10, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $1.3B | 267 | Aug 12, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $983M | 263 | May 14, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $867M | 223 | Feb 12, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $680M | 205 | Nov 13, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $598M | 182 | Jul 29, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $501M | 175 | May 8, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $629M | 195 | Feb 10, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $586M | 190 | Nov 15, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $576M | 183 | Aug 9, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $567M | 178 | May 13, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q4 2018 | $489M | 164 | Feb 14, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.